4mg CLS-TA Suprachoriodal Injection + Sham Procedure
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Uveitis
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
Trial Timeline
Nov 17, 2015 → Jan 18, 2018
NCT ID
NCT02595398About 4mg CLS-TA Suprachoriodal Injection + Sham Procedure
4mg CLS-TA Suprachoriodal Injection + Sham Procedure is a phase 3 stage product being developed by Clearside Biomedical for Uveitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02595398. Target conditions include Uveitis, Uveitis, Posterior, Uveitis, Anterior.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02595398 | Phase 3 | Completed |
Competing Products
20 competing products in Uveitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| triamcinolone acetonide (Triesence®) | Clearside Biomedical | Phase 1/2 | 33 |
| 4 mg CLS-TA Suprachoriodal Injection | Clearside Biomedical | Phase 3 | 69 |
| Baricitinib + Adalimumab | Eli Lilly | Phase 3 | 77 |
| Ixekizumab Prefilled Syringe | Eli Lilly | Approved | 85 |
| adalimumab | AbbVie | Phase 3 | 77 |
| Adalimumab + Prednisone + Placebo | AbbVie | Phase 3 | 77 |
| Adalimumab + Prednisone + Placebo | AbbVie | Phase 3 | 77 |
| Adalimumab | AbbVie | Approved | 85 |
| FTY720 + Oral Corticosteroid | Novartis | Phase 2 | 52 |
| AIN457 | Novartis | Phase 3 | 77 |
| Myfortic | Novartis | Pre-clinical | 23 |
| AIN457 + AIN457 + Placebo AIN457 | Novartis | Phase 3 | 77 |
| LFG316 + Conventional Therapy | Novartis | Phase 2 | 52 |
| Ranibizumab | Novartis | Phase 2 | 52 |
| AIN457 + Placebo | Novartis | Phase 3 | 77 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 77 |
| AEB071 | Novartis | Phase 2 | 52 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 77 |
| Myfortic + Decortin | Novartis | Phase 3 | 77 |
| AIN457 + AIN 457 + AIN457 | Novartis | Phase 2 | 52 |